ASCO Tumor Boards: Relapsed CLL

Product ID : ATB1805
Price: $15.00
You will receive a link to your product from customerservice@asco.org within 1 hour of purchase confirmation. Shipping charges do not apply to digital products.
E-mail to a friend

Purchase

Description

Chronic lymphocytic leukemia (CLL) is a form of NHL that arises from B lymphocytes. When most of the cancer cells are located in the bloodstream and the bone marrow, the disease is referred to as CLL, although the lymph nodes and spleen are often involved. Relapsed CLL is the term for disease that responded to therapy but, after 6 or more months, stopped responding. This is a case-based activity that includes a discussion of a 67-year-old male patient diagnosed with CLL after presenting with fatigue, 20lb weight loss, and diffuse lymphadenopathy. Two years later, his CLL relapsed with increasing lymphocyte count and generalized lymphadenopathy.

At the end of this course, learners should be able to:

1. Evaluate relevant disease and patient factors to inform treatment choice for a patient with CLL.

2. Appreciate unique considerations in the assessment of older patients with CLL.

3. Evaluate the role of targeted agents and combined modality regimens in the treatment of relapsed CLL.

4. Identify key side effects of targeted agents and apply appropriate supportive care measures.

5. Compare efficacy and toxicity of chemoimmunotherapy vs. targeted agents in specific patient populations. 

IMPORTANT NOTE: This course expires on September 19, 2020. Participants must complete all necessary course components by this date.